Javascript must be enabled to continue!
P-027 A CASE OF PSEUDOGOUT ATTACK AFTER ZOLEDRONIC ACID TREATMENT IN PRIMARY HYPERPARATHYROIDISM
View through CrossRef
Abstract
Introduction
Calcium pyrophosphate dihydrate (CPPD) deposition in the joints is an inflammatory arthropathy known as pseudogout (PG). Rare cases of pseudogout associated with bisphosphonate therapy have been reported in the literature. Here, we present a patient with primary hyperparathyroidism (PHP) who developed pseudogout in the elbow joint following bisphosphonate use.
Clinical Case
A 65-year-old female patient was evaluated due to hypercalcemia and diagnosed with primary hyperparathyroidism. No pathological focus was detected in ultrasonography and scintigraphy. Because of persistently high calcium levels and osteoporosis on bone densitometry, intravenous zoledronic acid (ZA) was administered. Three days after ZA treatment, the patient developed nausea and diffuse body pain. Laboratory evaluation revealed elevated creatinine levels, and she was admitted to the hospital with a preliminary diagnosis of acute kidney injury (AKI). On the third day of hospitalization, she developed pain, swelling, limited motion, and increased temperature in the right elbow. Since septic arthritis could not be excluded after orthopedic consultation, joint irrigation was performed. However, her complaints persisted, and joint culture revealed no bacterial growth. The patient was then evaluated by rheumatology, and pseudogout was considered. Systemic steroid therapy was initiated, leading to significant improvement in her symptoms.
Conclusion
Although bisphosphonates such as zoledronic acid (ZA) have an important role in the treatment of osteoporosis, potential complications should be kept in mind. In this case, the patient’s PHP, age, significant hypercalcemia at admission, and the rapid decrease in calcium levels after ZA treatment were predisposing factors for a PG attack. Pseudogout following ZA treatment is a rare complication reported in the literature.Table 1:Laboratory Parameters Before ZA, During AKI, and After Treatment
Title: P-027 A CASE OF PSEUDOGOUT ATTACK AFTER ZOLEDRONIC ACID TREATMENT IN PRIMARY HYPERPARATHYROIDISM
Description:
Abstract
Introduction
Calcium pyrophosphate dihydrate (CPPD) deposition in the joints is an inflammatory arthropathy known as pseudogout (PG).
Rare cases of pseudogout associated with bisphosphonate therapy have been reported in the literature.
Here, we present a patient with primary hyperparathyroidism (PHP) who developed pseudogout in the elbow joint following bisphosphonate use.
Clinical Case
A 65-year-old female patient was evaluated due to hypercalcemia and diagnosed with primary hyperparathyroidism.
No pathological focus was detected in ultrasonography and scintigraphy.
Because of persistently high calcium levels and osteoporosis on bone densitometry, intravenous zoledronic acid (ZA) was administered.
Three days after ZA treatment, the patient developed nausea and diffuse body pain.
Laboratory evaluation revealed elevated creatinine levels, and she was admitted to the hospital with a preliminary diagnosis of acute kidney injury (AKI).
On the third day of hospitalization, she developed pain, swelling, limited motion, and increased temperature in the right elbow.
Since septic arthritis could not be excluded after orthopedic consultation, joint irrigation was performed.
However, her complaints persisted, and joint culture revealed no bacterial growth.
The patient was then evaluated by rheumatology, and pseudogout was considered.
Systemic steroid therapy was initiated, leading to significant improvement in her symptoms.
Conclusion
Although bisphosphonates such as zoledronic acid (ZA) have an important role in the treatment of osteoporosis, potential complications should be kept in mind.
In this case, the patient’s PHP, age, significant hypercalcemia at admission, and the rapid decrease in calcium levels after ZA treatment were predisposing factors for a PG attack.
Pseudogout following ZA treatment is a rare complication reported in the literature.
Table 1:Laboratory Parameters Before ZA, During AKI, and After Treatment.
Related Results
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
ABSTRACT
Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patie...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
How zoledronic acid improves osteoporosis by acting on osteoclasts
How zoledronic acid improves osteoporosis by acting on osteoclasts
Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur. Zoledron...
Local Administration of Zoledronic Acid for Giant Cell Tumor of Bone
Local Administration of Zoledronic Acid for Giant Cell Tumor of Bone
Giant cell tumor of bone is a locally aggressive tumor with a high local recurrence rate. Several adjuvant therapies have been employed to reduce the recurrence rate, but their eff...
Effects of zoledronic acid combined with metformin on bones of DB/DB mice
Effects of zoledronic acid combined with metformin on bones of DB/DB mice
Abstract
Background
Diabetic patients are prone to osteoporosis. Both zoledronic acid and metformin have certain anti-osteoporotic effects.Here we explore the anti-osteopo...
SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
Abstract
In real practice, many patients with osteoporosis are poorly compliant with oral bisphosphonate, partly due to gastrointestinal side effects and partly due ...
Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
Abstract
Background: Severe hypophosphatemia may be seen following zoledronic acid infusion, however FGF23 elevation has not been previously reported.
...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...

